EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada

Lawrence Richer iD, Huong Luu, Karen J B Martins iD, Khanh Vu, Alexis Guigue, Kai On Wong, Phuong Uyen Nguyen, Thilinie Rajapakse, Tyler Williamson, Scott W Klarenbach

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Lawrence Richer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Dentistry, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Migraine Disorders, Botulinum Toxins, Type A, Neuromuscular Agents, Health Resources. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc., AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Understand health resource, medication use, and cost of adults with chronic migraine who received guideline‐recommended onabotulinumtoxinA (botulinum toxin) treatment frequency and then continued or reduced/stopped.

Background

Botulinum toxin may be a beneficial treatment for chronic migraine; the trajectory of health resources utilization among those with continued or reduced/stopped use is unclear.

Methods

A retrospective population‐based cohort study utilizing administrative data from Alberta, Canada (2012–2020), was performed. A cohort of adults who received ≥5 botulinum toxin treatment cycles for chronic migraine over 18 months (6‐month run‐in; 1‐year pre‐index period) were grouped into those who (1) continued use (≥3 treatments/year), or (2) stopped or reduced use (stopped for 6 months then received 0 or 1–2 treatments/year, respectively) over a 1‐year post‐index period. Health resources and medication use were described, and pre–post costs were assessed. A second cohort that received ≥3 treatments/year immediately followed by 1 year of stopped or reduced use was considered in sensitivity analysis.

Results

Pre–post health resource, medication use, and costs were similar among those with continued use ( n = 3336). Among those who stopped or reduced use ( n = 1099; 756 stopped, 343 reduced), health resource, medication use, and costs were lower in the post‐ (total median per‐person cost [IQR]: all‐cause $4851 [$8090]; migraine‐related $835 [$1915]) versus pre‐ (all‐cause $6096 [$7207]; migraine‐related $2995 [$1950]) index period (estimated cost ratios [95% CI]: total all‐cause 0.86 [0.79, 0.95]; total migraine‐related 0.44 [0.40, 0.48]). In the second cohort ( n = 3763), return to continued use (≥3 treatments/year) occurred in up to 70.4% in those with reduced use.

Conclusions

Of adults treated with botulinum toxin for chronic migraine, 75.2% had continued use, stable health resource and medication use, and costs over a 2 year period. In those that stopped/reduced use, the observed lower health resource and migraine medication use may indicate improved symptom control, but the resumption of guideline‐recommended treatment intervals after reduced use was common.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersBotulinum Toxins, Type ANeuromuscular AgentsHealth ResourcesHealth Care CostsHumansAlbertaMaleFemaleAdultRetrospective StudiesMiddle AgedChronic DiseaseYoung Adult

Stichwörter der Autor:innen

administrative databotulinum toxinchronic migraineonabotulinumtoxinAretrospective

Substanzen

Botulinum Toxins, Type ANeuromuscular Agentsonabotulinum toxin A

Autor:innen und Institutionen

  • Faculty of Medicine and Dentistry, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
  • Faculty of Medicine and Dentistry, Real World Evidence Unit, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Community Health Sciences and the Centre for Health Informatics, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
  • Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

ORCID-Profile: Lawrence Richer, Karen J B Martins

Förderung

  • AbbVie Inc.
  • AbbVie

Zitieren

APA

Richer, L., Luu, H., Martins, K. J. B., Vu, K., Guigue, A., Wong, K. O., Nguyen, P. U., Rajapakse, T., Williamson, T., & Klarenbach, S. W. (2023). Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14613

Vancouver

Richer L, Luu H, Martins KJB, Vu K, Guigue A, Wong KO, et al. Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14613

BibTeX
@article{Richer2023,
  author = {Richer, Lawrence and Luu, Huong and Martins, Karen J B and Vu, Khanh and Guigue, Alexis and Wong, Kai On and Nguyen, Phuong Uyen and Rajapakse, Thilinie and Williamson, Tyler and Klarenbach, Scott W},
  title = {Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14613}
}
Kostenlos starten →